4 Efficacy

4 Efficacy

This section describes efficacy outcomes from the published literature that the Committee considered as part of the evidence about this procedure. For more detailed information on the evidence, see the overview.

4.1 A case series of 69 patients with primary or metastatic pulmonary malignancies reported overall survival rates at 1 year, 2 years and 3 years as 75%, 54% and 29% respectively in patients with non‑small‑cell lung cancer (n=48), and 48%, 24% and 14% respectively in patients with pulmonary metastatic tumours (n=21).

4.2 A case series of 50 patients with primary or metastatic disease reported that 26% (13/50) of patients in whom the procedure had initial technical success (defined as no detectable enhancement on the initial post-ablation CT scan; achieved in 95% [63/66] of ablations) had recurrent disease at the ablation site 6 months after the initial ablation.

4.3 In a case series of 80 patients with pulmonary metastases, the mean time to tumour progression after ablation was 6 months.

4.4 In the case series of 80 patients with pulmonary metastases, re‑ablation of residual or recurrent lesions was performed in 49% (17/35) of lesions. Secondary tumour control (not otherwise defined) after re-ablation was successful in 53% (9/17) of these lesions, with no residual or recurrent tumour (within 6- to 9‑month follow‑up).

4.5 The specialist advisers listed completeness of treatment, overall survival, disease‑free survival, progression‑free survival and local control as key efficacy outcomes.

  • National Institute for Health and Care Excellence (NICE)